Polymorph A HDAC6 Inhibitor Stability and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HDAC6-associated diseases, particularly cancer, face challenges in efficacy and safety due to the limited specificity of HDAC inhibitors, which can affect gene regulation and result in significant side effects, and there is a need for more stable and effective drug formulations.
Innovation Solution
A polymorph A of a compound with specific X-ray powder diffraction peaks and thermal stability is developed, which is less affected by light, heat, and humidity, and has shown good efficacy in vivo, potentially offering a safer and more effective treatment option for HDAC6-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HDAC inhibitors are used to treat HDAC6-associated diseases, then therapeutic effect is improved, but side effects increase due to limited specificity affecting gene regulation
Solution Approach 1:
The invention segments the HDAC inhibitor market by developing a polymorph-specific formulation that selectively targets HDAC6 enzyme activity without broadly affecting other HDAC isoforms. The polymorph A crystal structure enables selective binding to HDAC6's active site, separating its therapeutic action from off-target effects on gene regulation pathways.
Solution Approach 2:
The polymorph A formulation exhibits localized therapeutic action at the HDAC6 enzyme level, with different properties compared to other HDAC inhibitors. The specific crystal packing and molecular arrangement in polymorph A create a unique interaction profile with HDAC6 that spares other biological systems from harmful effects.
2Ease of manufacture
If conventional HDAC inhibitor formulations are used, then drug delivery is simplified, but stability under various conditions deteriorates
Solution Approach 1:
The invention changes the physical and chemical parameters of the HDAC inhibitor by crystallizing it in polymorph A form, which has superior stability characteristics. This polymorph exhibits higher melting point, lower solubility, and greater resistance to degradation under light, heat, and humidity compared to other polymorphs or amorphous forms, while maintaining manufacturability through established crystallization protocols.
3Stability of the object's composition
If polymorph A is developed with specific stability characteristics, then stability under light, heat, and humidity is improved, but manufacturing complexity increases
Solution Approach 1:
The polymorph A formulation exhibits self-stabilizing properties where the crystal structure inherently resists degradation and transformation under various environmental conditions. The molecules in polymorph A are arranged in a configuration that maximizes intermolecular interactions, creating a thermodynamically stable structure that maintains its properties without requiring complex stabilization additives or processing controls.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorph A of the compound demonstrates stability and effectiveness in treating HDAC6-associated diseases with reduced side effects, as evidenced by its broad therapeutic prospects and stability under various conditions, including high temperature, humidity, and light exposure.
Implementation Method 1
The present disclosure provides a polymorph A of a compound of formula (I)... The polymorph A of the compound of formula (I) in the present disclosure is stable, less affected by light, heat and humidity
Implementation Method 2
the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 11.53 ± 0.2°, 18.46 ± 0.2°, and 23.60 ± 0.2°
Data Source
Figure 1~2
Figure 3
AI summary
Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases.